Merck’s Forward P/E Nearly Doubled to 17x in a Year. Here’s What Its Pipeline Must Deliver by 2030
Merck (MRK) and Daiichi Sankyo withdrew a U.S. approval application for their investigational cancer drug, citing insufficient data. Merck's stock is at $148.74, with a mid-target of $166 and a potential 12% total return. The company's pipeline is estimated to deliver $70B+ by the mid-2030s, but recent setbacks highlight risks. Analysts' FY2030 revenue estimates have risen to around $76B.
How this was made
The 30-second read
Why it matters
The regulatory setback likely curtails near‑term upside and could trigger a short‑term price dip.
Market read
First‑report of a failed FDA accelerated approval for a late‑stage oncology drug, affecting Merck's valuation and pipeline expectations.
What to watch
The withdrawal was voluntary; the companies retain Phase 3 enrollment and may re‑file later, mitigating long‑term damage.
Background
Merck's forward P/E has risen to 17x after a series of pipeline optimism, but the recent withdrawal underscores valuation risk.
Ticker impact
Merck and Daiichi Sankyo withdrew their FDA accelerated approval application for the investigational cancer drug ifinatamab deruxtecan after the agency said Phase 2 data fell short.
downward pressure as investors price in the missed approval and delayed pipeline revenue.
The withdrawal removes a near‑term catalyst and highlights execution risk for Merck's oncology franchise.
Market effects
Potential re‑rating of the broader oncology biotech sector as FDA scrutiny intensifies.
U.S. pharma stocks may see modest pullback amid heightened regulatory risk.
Limited to investors tracking large‑cap pharma pipelines; no broad market effect.
Counterpoint
If Merck can replace the lost candidate with other late‑stage assets, the setback may be temporary and the stock could rebound.
Key entities
- CompanyMerck & Co.
US‑listed pharmaceutical giant (ticker MRK).
- CompanyDaiichi Sankyo
Japanese pharma partner in the withdrawn application.
